ZERBAXA (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
ZERBAXA
Date registered
Evaluation commenced
Decision date
Approval time
243 (255 working days)
Active ingredients
ceftolozane sulfate, tazobactam sodium
Registration type
EOI
Indication
ZERBAXA (ceftolozane/tazobactam) is indicated for the treatment of adult and paediatric (birth to less than 18 years of age) patients with the following infections caused by designated susceptible microorganisms: